Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country
Por:
Cifuentes C., Lombana M., Vargas H., Laguado P., Ruiz-Patiño A., Rojas L., Navarro U., Vargas C., Ricaurte L., Arrieta O., Zatarain-Barron L., Zapata L., González G., Ortiz C., Bernal L., Restrepo J.G., Viola L., Grosso F., Zapata R., Mantilla W., Carranza H., Bustillo I., Llinas N., Duarte R., Rodríguez J., Archila P., Ávila J., Bermúdez M., Gámez T., Sotelo C., Otero J., Forero E., Lema M., Limpias C., Ordóñez-Reyes C., Mejía S., Rolfo C., Rosell R., Cardona A.F.
Publicada:
1 ene 2023
Resumen:
Purpose: Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country. Methods: In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians’ request in the clinical care for therapy decisions. Kaplan–Meier survival curves were estimated to characterize the time-to-event variables. Results: Patients median age was 61 years (range: 14–87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment (P =.7). Conclusion: CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients. © The Author(s) 2023.
Filiaciones:
Cifuentes C.:
Clinical Oncology Department, Hospital Universitario Mayor de Mederi, Bogotá, Colombia
Lombana M.:
Hematology and Oncology Department, Clínica de Occidente, Cali, Colombia
Vargas H.:
Oncology Department, Clínica Colsanitas, Bogotá, Colombia
Laguado P.:
Clinical Research Institute, Clínica del Country, Bogotá, Colombia
Ruiz-Patiño A.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Rojas L.:
Oncology Department, Clínica Colsanitas, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Clinical Oncology Department, Clínica del Country, Bogotá, Colombia
Navarro U.:
Clinical Oncology Department, Clínica General del Norte, Barranquilla, Colombia
Vargas C.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Clinical Oncology Department, Clínica del Country, Bogotá, Colombia
Ricaurte L.:
Pathology Department, Mayo Clinic, Rochester, MN, United States
Arrieta O.:
Thoracic Oncology Unit, National Cancer Institute (INCan), México City, Mexico
Zatarain-Barron L.:
Thoracic Oncology Unit, National Cancer Institute (INCan), México City, Mexico
Zapata L.:
Oncology Department, San Vicente Fundación, Medellín, Colombia
González G.:
Centro Integral del Cáncer, Clínica de Occidente, Cali, Colombia
Ortiz C.:
Clinical Oncology Department, Clínica del Country, Bogotá, Colombia
Bernal L.:
Oncology Department, Clínica Colsanitas, Bogotá, Colombia
Clinical Oncology Department, Clínica Marly, Bogotá, Colombia
Restrepo J.G.:
Oncology Department, Fundación Valle de Lili, Cali, Colombia
Viola L.:
Thoracic Oncology Unit, Fundación Neumológica Colombiana, Bogotá, Colombia
Grosso F.:
Oncology Department, Medical Plus, Bogotá, Colombia
Zapata R.:
Oncology Department, Clínica Cardio-VID, Medellín, Colombia
Mantilla W.:
Hematology and Oncology Department, Fundación Cardio Infantil, Bogotá, Colombia
Carranza H.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Clinical Oncology Department, Clínica del Country, Bogotá, Colombia
Bustillo I.:
Oncology Department, Clínica Porto Azul, Barranquilla, Colombia
Llinas N.:
Oncology Department, Clínica Vida, Medellín, Colombia
Duarte R.:
Oncology Department, Clínica Colsanitas, Bogotá, Colombia
Rodríguez J.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Archila P.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Ávila J.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Bermúdez M.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Gámez T.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Sotelo C.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Otero J.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Forero E.:
Clinical Oncology Department, Hospital Universitario Mayor de Mederi, Bogotá, Colombia
Lema M.:
Hematology and Oncology Department, Clínica Astorga, Medellín, Colombia
Limpias C.:
Pathology Department, Bogotá, Inmunoprint, Colombia
Ordóñez-Reyes C.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Mejía S.:
Oncology Department, San Vicente Fundación, Medellín, Colombia
Clinical Oncology Department, San Vicente Fundación, Medellín, Colombia
Rolfo C.:
Thoracic Oncology Center, Icahn School of Medicine at Mount Sinai Tisch Cáncer Center, Mount Sinai Hospital System, New York, NY, United States
Rosell R.:
Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Barcelona, Spain
Cardona A.F.:
Foundation for Clinical and Applied Cancer Research - FICMAC, Bogotá, Colombia
Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad el Bosque, Bogotá, Colombia
Direction of Research, Science and Education, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC), Bogotá, Colombia
All Open Access; Gold Open Access; Green Open Access
|